Lung oncology Clinical Trials in New York, NY
As of June 2026, 130 paid clinical trials are recruiting for Lung oncology in New York, New York. Lung oncology trials investigate EGFR, ALK, KRAS, and other driver-mutation targeted therapies alongside immunotherapy combinations for non-small cell, small cell, and mesothelioma studies. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
130 clinical trials for Lung oncology
·Clear filters·↓ Download CSVA Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
A Study of LY4175408 in Participants With Advanced Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
SLV-154 Treatment of Metastatic Solid Tumors
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Brodalumab in the Treatment of Immune-Related Adverse Events
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
About research studies in New York
New York has approximately 3,501 recruiting research studies across a wide range of therapeutic areas. New York is home to leading academic medical centers such as Memorial Sloan Kettering, Weill Cornell Medicine, Mount Sinai, NYU Langone, and Columbia University Irving Medical Center. These institutions anchor a research ecosystem that covers oncology, cardiology, neurology, and rare disease.
Top Research Study Locations in New York
Researchers run research studies in New York, NY at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Breast Cancer, Prostate Cancer, Endometrial Cancer | 481 |
| NYU Langone Health | Lung Cancer, Prostate Cancer, Cardiovascular Diseases | 309 |
| Icahn School of Medicine at Mount Sinai | Myelofibrosis, Prostate Cancer, Advanced Solid Tumor | 263 |
| Columbia University Irving Medical Center | Obesity, Insulin Resistance, Prostate Cancer | 187 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Breast Cancer, Multiple Myeloma, Metastatic Breast Cancer | 153 |
| Weill Cornell Medicine | Heart Failure, Depression, Prostate Cancer | 141 |
| Columbia University Medical Center | Breast Cancer, Advanced Solid Tumor, Coronary Artery Disease | 135 |
| Mount Sinai Hospital | Acute Myeloid Leukemia, Heart Failure, Anatomic Stage IV Breast Cancer AJCC v8 | 132 |
| Columbia University | Amyotrophic Lateral Sclerosis, Colorectal Cancer, Multiple Myeloma | 113 |
| Hospital for Special Surgery | Opioid Use, Rheumatoid Arthritis, Systemic Lupus Erythematosus | 69 |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Stage IV Renal Cell Cancer AJCC v8 | 64 |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Acute Myeloid Leukemia | 61 |
| Lenox Hill Hospital | Atrial Fibrillation, Anatomic Stage II Breast Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 55 |
| Weill Cornell Medical College | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 49 |
| Mount Sinai | Ovarian Cancer, AML, Advanced Solid Tumors | 44 |
| Mount Sinai West | Breast Cancer, Intracerebral Hemorrhage, Anatomic Stage II Breast Cancer AJCC v8 | 43 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | Breast Cancer, Prostate Cancer, Adult Cancer Patients | 38 |
| NYP/Weill Cornell Medical Center | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8 | 35 |
| New York University | Inflammatory Bowel Disease (IBD), Adenine Phosphoribosyltransferase Deficiency, Arrhythmogenic Right Ventricular Cardiomyopathy | 33 |
| Memorial Sloan-Kettering Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer | 27 |
| Mount Sinai Chelsea | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Cancer | 24 |
| Manhattan Eye Ear and Throat Hospital | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 22 |
| NYU Langone | Gout, Acute Gastrointestinal Bleeding, Acute Gout Flare | 21 |
| Montefiore Medical Center | Mitral Regurgitation, Coronary Artery Disease, AML, Adult | 20 |
| NYU Langone Medical Center | Mesothelioma, NSCLC, Non Small Cell Lung Cancer | 20 |
Active & Upcoming Studies in New York (2026)
Recruiting trials in New York grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (1,213 active studies)
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) · Phase 2 · Columbia University
- Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening · VA Office of Research and Development
Neurology & pain (207 active studies)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau · Phase 1 · Columbia University
- Opioid Dispenser for Microdiscectomy/Laminectomy · Hospital for Special Surgery, New York
Cardiovascular (194 active studies)
Mental health & behavior (105 active studies)
- Permanent Supportive Housing Overdose Prevention+ Study · NYU Langone Health
- Technology dRiven Enhancement to Engage & Connect · Weill Medical College of Cornell University
Diabetes & metabolic (102 active studies)
- South Asians With Type 2 Diabetes at Risk for Depression · NYU Langone Health
- Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · Columbia University
HIV / STI (48 active studies)
Pediatric (34 active studies)
Vaccines (22 active studies)
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction · Phase 2 · Icahn School of Medicine at Mount Sinai
- Harnessing Optimism and Perseverance in the Face of Long COVID-Español · Icahn School of Medicine at Mount Sinai
Eye & vision (18 active studies)
- Know Your Pressures NYC · Columbia University
- Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) · Phase 1 · Life Biosciences Inc.
Common conditions studied in New York
- Breast Cancer (93 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (73 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Multiple Myeloma (51 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Advanced Solid Tumor (42 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Ovarian Cancer (42 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Colorectal Cancer (39 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
Leading research sponsors in New York
- Memorial Sloan Kettering Cancer Center
- NYU Langone Health
- Columbia University
- Icahn School of Medicine at Mount Sinai
- Weill Medical College of Cornell University
Local regulations and guidelines
Clinical trials in New York are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials conducted in New York must also comply with the NY SHIELD Act's data-protection requirements and additional oversight from the New York State Department of Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in New York. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in New York
Hipa.ai aggregates every recruiting study in New York from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in New York?
There are approximately 3,501 recruiting clinical trials in New York, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New York pay participants?
Most recruiting trials in New York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New York?
The most common conditions under active study in New York include Breast Cancer (93), Prostate Cancer (73), Multiple Myeloma (51), Advanced Solid Tumor (42), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New York?
Recruiting research sites in New York include Memorial Sloan Kettering Cancer Center, NYU Langone Health, Icahn School of Medicine at Mount Sinai, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New York right now?
The largest active categories in New York are Cancer & tumors (1,213), Neurology & pain (207), Cardiovascular (194). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.